Supercharged immune cells aim to stop leukemia relapse

NCT ID NCT06138587

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests whether specially trained natural killer (NK) cells, called CIML NK cells, along with interleukin-2 (IL-2), can safely prevent leukemia from coming back after a stem cell transplant. The study enrolls 15 adults with high-risk acute myeloid leukemia, myelodysplastic syndrome, or related blood cancers who still have signs of disease before transplant. Participants receive one infusion of donor-derived CIML NK cells plus IL-2 shots, and researchers monitor for side effects and the best dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Cytokine-induced memory-like natural killer (CIML NK) cells and interleukin-2 (IL-2)
What this could lead to
If successful, this approach could help prevent leukemia relapse after a stem cell transplant, improving long-term survival for high-risk patients.
What could go wrong
This is a very early phase 1 trial with only 15 participants, focused on safety and dosing. It may not show a clear benefit, and there are risks of serious side effects from the cell infusion and IL-2.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Brigham and Women's Hospital

    NOT_YET_RECRUITING

    Boston, Massachusetts, 02215, United States

  • Dana-Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.